Author

Paolo Fabrizio Caimi

Case Comprehensive Cancer CenterORCID 0000-0003-1436-0464Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

David N. WaldiD· 2 shared Alberto J. ArribasiD· 1 shared Alessio BruscagginiD· 1 shared Anastasios StathisiD· 1 shared Chiara TarantelliiD· 1 shared Claire E. FritziD· 1 shared Davide RossiiD· 1 shared Eleonora CannasiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

David N. WaldORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 22, 2025

B-cell activating factor plays a critical role in CAR-T cell-associated cytokine release syndrome

Claire E. Fritz, Leland L. Metheny, David N. Wald…·Reshmi Parameswaran

This study identifies BAFF as a key mediator of CAR-T cell-related cytokine release syndrome and shows that neutralizing BAFF reduces cytokine production without affecting CAR-T cell function.

DOI 10.1101/2025.11.22.689920

humanproteomics

𝕏 PostBluesky

Cancer BiologyHaematologicaPeer-reviewedMay 9, 2024

Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach

Chiara Tarantelli, David N. Wald, Nicolas Munz…·Francesco Bertoni

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

21 citationstop 2%

humanexperimental assay

𝕏 PostBluesky